Wednesday, May 05, 2021 8:27:54 AM
Go Leo & IPIX!
Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral
Innovation wanted to bring to the attention of shareholders a recent review article that supports defensins as a source of potential therapeutics against viral infections.
Solanki SS, Singh P, Kashyap P, Sansi MS, Ali SA.
“Promising role of defensins peptides as therapeutics to combat against viral infection.”
Microb Pathog. 2021 Apr 29:104930. doi: 10.1016/j.micpath.2021.104930. Epub ahead of print. PMID: 33933603.
https://www.sciencedirect.com/science/article/pii/S0882401021002023
As the article conveys, newer mechanistic insights are elucidating the intrinsic and multi-faceted abilities of defensins—a type of small antimicrobial peptide—to confer protection against many types of viruses.
Brilacidin, a defensin-mimetic designed and optimized to capture the biological properties of naturally occurring defensins, was highlighted in the article:
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
Leo Ehrilich Quote "If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM